← Back to Clinical Trials
RecruitingPhase 3NCT05358535

Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionAnesthesia
SponsorUniversity of Texas Southwestern Medical Center
Study TypeINTERVENTIONAL
PhasePhase 3
Enrollment200
SexALL
Min Age18 Years
Max AgeN/A
Start Date2022-09-19
Completion2027-01
Interventions
Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).

Eligibility Criteria

Inclusion Criteria: 1. Adult patients (age ≥18 years old) 2. Having endoscopic procedure at CUH with anesthesia 3. ASA 3 or above 4. Ejection Fraction test result available Exclusion Criteria: 1. Known allergies or adverse reactions to study drugs or study drug components or preservatives 2. Patient refusal 3. Clinician refusal 4. Documented cognitive impairments precluding subject ability to consent for themselves unless a surrogate documented legally acceptable decision maker consents for patient participation 5. Prisoner or incarcerated or patients held by law enforcement officials in custody 6. Pregnancy or patient refusal for pregnancy testing or screening (standard UTSW policy and protocol requires pregnancy testing for appropriate patients prior to anesthesia)

Related Trials